Form 4: Tyra Biosciences Director Robert J. More Granted 22,200 Stock Options

Tyra Biosciences, Inc. Director Robert J. More was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

Summary

• Robert J. More, a Director of Tyra Biosciences, Inc. (TYRA), was granted 22,200 stock options on May 29, 2025.
• The options have an exercise price of $9.25 per share.
• The grant was made under the Issuer's Non-Employee Director Compensation Program.
• The options begin vesting monthly, with 1/12th of the total shares vesting each month following the May 29, 2025 grant date.
• Any unvested portion will vest on the date of the next annual stockholders' meeting if it occurs prior to the first anniversary of the grant date, contingent on continuous service.
• The options expire on May 28, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine compensation event for a director, not indicative of significant positive or negative operational or financial news for the company.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options' value increases with the company's stock price.
• It indicates continued commitment and service of a director to the company.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if the options are exercised.

Future Outlook

The stock options will vest monthly over a 12-month period following the grant date, or earlier upon the next annual meeting of stockholders under certain conditions, indicating a future commitment to the director's service.

Industry Context

This Form 4 filing details a routine compensation event for a director, common across publicly traded companies, particularly in the biotechnology sector like Tyra Biosciences, to attract and retain talent and align management incentives with shareholder value.

Related Party Transactions

• The grant of stock options to Robert J. More, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Next Steps

• Monthly vesting of 1/12th of the granted stock options will commence following May 29, 2025.
• The remaining unvested options may vest earlier if the next annual meeting of stockholders occurs before the first anniversary of the grant date.

Key Dates

Keywords

Tyra Biosciences, TYRA, SEC Form 4, stock options, director compensation, equity grant, insider transaction, vesting schedule